Please assess the completion status of the following clinical trial:

Trial Title: Sweet Preference and Alcohol Craving

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women between the ages of 18 and 65 meeting DSM-IV criteria for current alcohol dependence.~2. More than 14 drinks (women) or 21 drinks (men) per week including at least 2 heavy drinking days/week on average (men \> 5 drinks/day; women \> 4 drinks/day) during a consecutive 30-day period within the 90 days prior to screening.~3. Ability to understand and sign written informed consent.~4. Must have a 0.0 gms/dL breathalyzer reading on the day of screening and 0.0 gms/dL on the day of randomization.~5. Must be willing to refrain from drinking for three days prior to randomization day.~6. Express a desire to achieve abstinence or to greatly reduce alcohol consumption.~7. Must have a stable residence and be able to identify an individual who could locate subject if needed.~Exclusion Criteria:~1. Clinically significant medical disease that might interfere with the evaluation of the study medication or present a safety concern (e.g., cirrhosis, unstable hypertension, seizure disorder, use of opiate medication).~2. Clinically significant psychiatric illness including: any psychotic disorder, bipolar disorder, severe depression, or suicidal ideation.~3. Other substance abuse or dependence disorder other than nicotine or alcohol.~4. Concurrent use of any psychotropic medication including antidepressants, mood stabilizers, antipsychotics, anxiolytics, stimulants, or hypnotics with the exception of stable doses of antidepressants for one month.~5. History of complicated alcohol withdrawal, i.e. withdrawal seizure or delirium tremens.~6. AST, or ALT \> 3 times Upper Limit of Normal (ULN) or bilirubin \> ULN.~7. Positive urine toxicology screen with the exception of cannabis. Individuals with positive cannabis screens will be excluded only if they have a history of cannabis dependence.~8. Pregnant women and women of childbearing potential who do not practice a medically acceptable form of birth control (oral or depot contraceptive, or barrier methods such as diaphragm or condom with spermicidal) and women who are breast feeding.~9. Individuals requiring inpatient treatment or more intense outpatient treatment for their alcohol dependence.~10. Participation in any clinical trial within the past 60 days.~11. Court-mandated participation in alcohol treatment or pending incarceration.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: ACTIVE_COMPARATOR): Sweet Liker, High Craver Half of this group will be on naltrexone the other half will be on placebo. All subjects will receive Brenda Therapy Sessions
- Arm 2 (Type: ACTIVE_COMPARATOR): Sweet Liker - Low Craver Half of this group will be on naltrexone the other half will be on placebo. All subjects will receive Brenda Therapy Sessions
- Arm 3 (Type: ACTIVE_COMPARATOR): Sweet Disliker - High Craver. Half of this group will be on naltrexone the other half will be on Placebo. All subjects will receive Brenda Therapy Sessions
- Arm 4 (Type: ACTIVE_COMPARATOR): Sweet Disliker - Low Craver; half of this group will be on naltrexone the other half on placebo. All subjects will receive Brenda Therapy Sessions

Based on this trial design, predict the completion outcome and termination type (if applicable).